Related Experiment Video
Updated: Jul 3, 2026
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Perioperative tislelizumab for early-stage hepatocellular carcinoma: A phase II trial with integrated tumour
Lu Chen1, Ruyu Han1, Shujie Zhai1
1Department of Hepatobiliary Cancer, Liver cancer research center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
Aims:
It is controversial whether monotherapy with immunotherapeutics is effective in early-stage hepatocellular carcinoma (HCC). We evaluated immunotherapy monotherapy as an initial neoadjuvant strategy.
Methods:
This prospective, single-arm, phase II trial of an adaptive neoadjuvant strategy enrolled patients with resectable, early-stage HCC. All patients received tislelizumab monotherapy; non-responders received subsequent lenvatinib combination therapy preoperatively.
Results:
For the overall efficacy of all 36 patients, the objective response rates were 13.9% and 30.6% as per the Response Evaluation Criteria in Solid Tumours v1.1 and modified Response Evaluation Criteria in Solid Tumours, respectively. Among the 33 patients who underwent resection, the major pathological response rate was 33.3% and the pathological complete response rate was 15.2%. Overall, grade ≥ 3 treatment-emergent adverse events occurred in 11.1%, with no surgical delays. Monotherapy responses were predicted by pretreatment tumour microenvironment features. Immune-regulatory cancer-associated fibroblasts colocalized with T cells identified responders, whereas angiogenic-metabolic signatures predicted resistance. A multimodal model integrating blood-based and imaging biomarkers accurately identified monotherapy-sensitive patients (average precision, 0.9167). The specificity for identifying responders was 100%.
Conclusions:
These preliminary findings suggest that neoadjuvant immunotherapy monotherapy exhibits promising antitumour activity and demonstrates a manageable safety profile in early-stage HCC. The tailored stratification approach appears clinically feasible and may help minimize unnecessary exposure to combination therapy-related toxicity while retaining tentative therapeutic efficacy.
